TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

On the Grid

From the shale fields to the cooling towers, Trib Total Media covers the energy industry in Western Pennsylvania and beyond. For the latest news and views on gas, coal, electricity and more, check out On the Grid today.

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Large-scale batteries are integral in shift to renewable energy
  2. Plastics, tech sectors crucial to cracker plants
  3. Energy Spotlight: Steve Anthos
  4. 113 Federal Reserve staffers earn more than chief Yellen
  5. Hackers rip into heart of open-source software
  6. Without pipelines, gas can’t get to demand
  7. Student loan debt presents paradox
  8. Open enrollment puts varied impact of health care law back in focus
  9. Universal theme park swings into Beijing
  10. Mortgage in reach despite few dings
  11. BNY Mellon profits up in third quarter
Subscribe today! Click here for our subscription offers.